SmcX inhibitors belong to a class of chemical compounds that have garnered interest within the realm of molecular research due to their potential to modulate the activity of the SmcX protein. SmcX, also known as KDM5C, is a gene that encodes a lysine-specific demethylase and contributes to epigenetic regulation by removing methyl groups from specific lysine residues on histone proteins. The pursuit of SmcX inhibitors arises from the recognition of their involvement in various biological processes, including gene expression, cellular differentiation, and chromatin structure, thus offering a unique avenue to explore the molecular mechanisms underlying these phenomena. These inhibitors encompass a variety of chemical structures and modes of action. Some SmcX inhibitors are characterized as small molecules, with their design targeting specific pockets or active sites on the SmcX protein. By binding to these regions, they interfere with the enzymatic demethylation activity of SmcX, impacting its ability to modify histone proteins and potentially influencing gene expression patterns. Peptide-based inhibitors are also explored, which involve short sequences found in SmcX itself or related proteins. These peptides may competitively interact with specific domains of SmcX, potentially disrupting its interactions with other proteins involved in epigenetic processes.
Furthermore, research efforts have unveiled compounds that act as "suicide" inhibitors. These molecules are metabolically activated to form reactive intermediates that covalently bind to the catalytic sites of SmcX, irreversibly inhibiting its enzymatic function. Such mechanisms of action hold significance in deciphering the intricate dynamics of SmcX within epigenetic pathways. Computational approaches have further contributed to the identification of potential SmcX inhibitors. Through virtual screening and molecular docking simulations, researchers can assess the binding affinities of various compounds to specific sites on the SmcX protein. This aids in selecting candidates for further experimental validation and provides insights into the structural basis of their interactions. In summary, SmcX inhibitors constitute a diverse chemical class that holds promise for deciphering the regulatory roles of SmcX in epigenetic processes. By targeting specific domains or catalytic sites on the protein, these inhibitors offer a means to dissect the complex interplay of epigenetic modifications and gene expression regulation. While their applications beyond fundamental research are not discussed here, SmcX inhibitors provide valuable tools to delve into the intricate mechanisms governing cellular processes on a molecular level.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
JIB 04 | 199596-05-9 | sc-397040 | 20 mg | $177.00 | ||
JIB-04 is a chemical compound that has been explored as an inhibitor of lysine demethylases, including SMCX. It falls into the category of Jumonji inhibitors, compounds designed to target the catalytic domain of lysine demethylases, including SMCX. These inhibitors hinder the enzymes' capacity to eliminate methyl groups from histone proteins. JIB-04 has displayed efficacy against SMCX and related demethylases in studies involving cells and research models. | ||||||
GSK J1 | 1373422-53-7 | sc-391113 sc-391113A | 10 mg 50 mg | $193.00 $813.00 | ||
GSK-J1 is an additional inhibitor that focuses on the Jumonji demethylase family, which includes SMCX. This compound was crafted to hinder the catalytic function of these enzymes by binding to their active sites. GSK-J1 has proven its effectiveness in impeding SMCX-related demethylation in laboratory conditions and has been applied in research to probe the consequences of lysine demethylase inhibition. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP2509 is a chemical inhibitor that has been identified as targeting various Jumonji demethylases, including SMCX. It operates by obstructing the demethylase activity, thereby influencing the epigenetic modifications mediated by these enzymes. SP2509 has been utilized in investigations to examine the roles played by Jumonji demethylases in diverse cellular processes. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999 is a chemical inhibitor that has been studied for its ability to inhibit KDM5C/SMCX. It functions by binding to the catalytic domain of KDM5C, thereby obstructing its demethylase activity. UNC1999 has been utilized in cellular and animal studies to shed light on the role of KDM5C in a range of biological contexts. | ||||||